Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.

Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J.

Mol Cancer Res. 2019 Sep;17(9):1931-1944. doi: 10.1158/1541-7786.MCR-18-0923. Epub 2019 Jun 3.

PMID:
31160383
2.

SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.

Hernández-Llodrà S, Segalés L, Safont A, Juanpere N, Lorenzo M, Fumadó L, Rodríguez-Vida A, Cecchini L, Bellmunt J, Lloreta-Trull J.

Prostate. 2019 Jul;79(10):1156-1165. doi: 10.1002/pros.23830. Epub 2019 May 15.

PMID:
31090082
3.

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.

Martínez-Bosch N, Rodriguez-Vida A, Juanpere N, Lloreta J, Rovira A, Albanell J, Bellmunt J, Navarro P.

Nat Rev Urol. 2019 Jul;16(7):433-445. doi: 10.1038/s41585-019-0183-5. Review.

PMID:
31015643
4.

Treatment of Metastatic Urothelial Cancer in 2018.

Bellmunt J, Rodriguez-Vida A.

JAMA Oncol. 2019 Jun 1;5(6):904-905. doi: 10.1001/jamaoncol.2019.0182. No abstract available.

PMID:
30973581
5.

The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.

Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B.

Int J Cancer. 2019 Oct 1;145(7):1970-1981. doi: 10.1002/ijc.32238. Epub 2019 Mar 23.

PMID:
30807643
6.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.

Eur Urol. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26.

7.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.

J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.

PMID:
30625039
8.

The Cancer Genome Atlas Project in Bladder Cancer.

Rodriguez-Vida A, Lerner SP, Bellmunt J.

Cancer Treat Res. 2018;175:259-271. doi: 10.1007/978-3-319-93339-9_12.

PMID:
30168126
9.

Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.

Rodriguez-Vida A, Perez-Gracia JL, Bellmunt J.

Clin Cancer Res. 2018 Dec 15;24(24):6115-6124. doi: 10.1158/1078-0432.CCR-17-3108. Epub 2018 Jul 10. Review.

PMID:
29991503
10.

Avelumab for the treatment of urothelial cancer.

Rodriguez-Vida A, Bellmunt J.

Expert Rev Anticancer Ther. 2018 May;18(5):421-429. doi: 10.1080/14737140.2018.1448271. Epub 2018 Mar 14. Review.

PMID:
29540084
11.

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

Rodriguez-Vida A, Torregrosa MD, Pinto Á, Climent MÁ, Olmos D, Carles J.

Clin Transl Oncol. 2018 Jun;20(6):679-686. doi: 10.1007/s12094-017-1785-0. Epub 2017 Nov 2. Review.

PMID:
29098556
12.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
13.

New treatment options for metastatic renal cell carcinoma.

Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH.

ESMO Open. 2017 May 9;2(2):e000185. doi: 10.1136/esmoopen-2017-000185. eCollection 2017. Review.

14.

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.

Rodriguez-Vida A, Strijbos M, Hutson T.

ESMO Open. 2016 May 25;1(3):e000013. eCollection 2016. Review.

15.

Complexity of FGFR signalling in metastatic urothelial cancer.

Rodriguez-Vida A, Saggese M, Hughes S, Rudman S, Chowdhury S, Smith NR, Lawrence P, Rooney C, Dougherty B, Landers D, Kilgour E, Arkenau HT.

J Hematol Oncol. 2015 Oct 24;8:119. doi: 10.1186/s13045-015-0221-6.

16.

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN.

Drug Des Devel Ther. 2015 Jun 29;9:3325-39. doi: 10.2147/DDDT.S69433. eCollection 2015. Review.

17.

Precision medicine for prostate cancer.

Galazi M, Rodriguez-Vida A, Ng T, Mason M, Chowdhury S.

Expert Rev Anticancer Ther. 2014 Nov;14(11):1305-15. doi: 10.1586/14737140.2014.972948. Epub 2014 Oct 30. Review.

PMID:
25354871
18.

Is there an antiandrogen withdrawal syndrome with enzalutamide?

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S, Payne H, de Bono J, Chowdhury S.

BJU Int. 2015 Mar;115(3):373-80. doi: 10.1111/bju.12826. Epub 2014 Oct 24.

19.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

20.

Mammalian target of rapamycin (mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?

Rodriguez-Vida A, Chau NM, Chowdhury S.

BJU Int. 2014 Mar;113(3):350-1. doi: 10.1111/bju.12493. No abstract available.

21.

Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.

Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, De Bono JS.

Eur J Cancer. 2014 Mar;50(5):1042-3. doi: 10.1016/j.ejca.2013.12.016. Epub 2014 Jan 13. No abstract available.

PMID:
24433842
22.

Cytoreductive nephrectomy: past, present and future.

Galazi M, Rodriguez-Vida A, Josephides E, Chau NM, Chowdhury S.

Expert Rev Anticancer Ther. 2014 Mar;14(3):271-7. doi: 10.1586/14737140.2014.864240. Epub 2014 Jan 6. Review.

PMID:
24392671
23.

The role of metastasectomy in renal cell carcinoma.

Josephides E, Rodriguez-Vida A, Galazi M, Chowdhury S, Suder A.

Expert Rev Anticancer Ther. 2013 Dec;13(12):1363-71. doi: 10.1586/14737140.2013.856762. Review.

PMID:
24236818
24.

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.

Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25.

PMID:
24074764
25.

Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry.

Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, Møller H.

BJU Int. 2013 Jul;112(2):182-9. doi: 10.1111/bju.12212.

Supplemental Content

Loading ...
Support Center